A federal jury in Illinois awarded an Oregon man $3.2 million in a retrial of a “low testosterone” case that originally netted $150 million.
Monday’s verdict includes $200,000 in compensatory damages and $3 million in punitive damages. The verdict is the fourth in federal court involving a low testosterone gel sold by Abbott Laboratories and AbbVie Inc. that plaintiffs claim has caused heart attacks and blood clots. Plaintiffs won another $140 million verdict last year, while Abbott and AbbVie won a defense verdict in January.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
